The ESMO-MCBS Scorecards allows you to filter either by Agent, Tumour or Score giving priority to different criteria such as Agent and Tumour Type and Tumour sub-type and Tumour sub-group in the Curative or Non-curative setting. This content will be updated regularly and communicated to ESMO Members.
First-line treatment of extensive-stage SCLCCASPIAN
Thoracic Malignancies
Small-cell Lung Cancer
-
CASPIAN
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Brigatinib
-
Crizotinib
Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non small cell lung cancer (NSCLC) previously not treated with an ALK inhibitorALTA-1L
Thoracic Malignancies
Non-small-cell Lung Cancer
ALK+
ALTA-1L
4
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
4
Niraparib
-
Placebo
Maintenance treatment for advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapyPRIMA/ENGOT-OV26/COG-3012
Gynaecological Malignancies
Ovarian, fallopian tubes and peritoneum cancer
-
PRIMA/ENGOT-OV26/COG-3012
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Atezolizumab
Bevacizumab
Sorafenib
Advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy IMbrave150
Gastrointestinal Cancers
Hepatobiliary Cancers - Hepatocellular Carcinoma
-
IMbrave150
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Olaparib
-
Enzalutamide or abiraterone (crossover allowed)
Treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agentPROfound
Genitourinary Cancers
Prostate cancer
Patients with ≥1 alteration in BRCA1, BRCA2 or ATM
PROfound
3
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
3
Olaparib
Bevacizumab
Placebo plus bevacizumab
Maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instabilityPAOLA-1
Gynaecological Malignancies
High-grade epithelial ovarian, fallopian tube or primary peritoneal cancer
HRD+ BRCA mutation
PAOLA-1
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Selpercatinib
-
Single arm
Treatment of adults with RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with sorafenib and/or lenvatinibLIBRETTO-001 (Cohort 1)
Endocrine Tumours
Thyroid cancer - differentiated
RET fusion-positive
LIBRETTO-001 (Cohort 1)
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Encorafenib
Cetuximab
Either irinotecan or FOLFIRI with cetuximab
In combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapyBEACON CRC
Gastrointestinal Cancers
Colorectal Cancer
BRAF V600E
BEACON CRC
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Avelumab
Best supportive care
Best supportive care
First-line maintenance treatment of adult patients who are progression-free following platinum-based ChTJAVELIN Bladder 100
Genitourinary Cancers
Urothelial Carcinoma
-
JAVELIN Bladder 100
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Lurbinectedin
-
Single arm
Metastatic SCLC with disease progression on or after platinum-based ChTPM1183-B-005-14
Thoracic Malignancies
Small-cell Lung Cancer
-
PM1183-B-005-14
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Nivo/Ipi (nivolumab and ipilimumab)
-
Chemotherapy
First-line treatment for patients with mNSCLC expressing PD-L1 (≥1%) with no EGFR or ALK genomic tumour aberrationsCheckMate 227
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 ≥1%
CheckMate 227
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Selpercatinib
-
Single arm
Treatment for adult patients who require systemic therapy following prior treatment with immunotherapy and/or platinum-based ChTLIBRETTO-001
Thoracic Malignancies
Non-small-cell Lung Cancer
RET fusion-positive
LIBRETTO-001
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Sacituzumab govitecan-hziy
-
Single arm (Phase I/II)
Treatment for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic diseaseIMMU-132-01
Breast Cancer
Breast Cancer
Triple-negative
IMMU-132-01
2
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
2
Neratinib
Capecitabine
Lapatinib plus capecitabine
Treatment of HER2-positive breast cancer patients who have received two or more prior anti-HER2 based regimens in the metastatic settingNALA
Breast Cancer
Breast Cancer
HER2+
NALA
1
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
1
Selpercatinib
-
Single arm
Treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 3)
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
LIBRETTO-001 (Cohort 3)
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Selpercatinib
-
Single arm
As monotherapy for the treatment of adult and adolescents ≥12 years of age with advanced RET-mutant medullary thyroid cancer (MTC) LIBRETTO-001 (Cohort 4)
Endocrine Tumours
Thyroid Cancer - medullary
RET-mutant
LIBRETTO-001 (Cohort 4)
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Ripretinib
-
Placebo (Crossover allowed)
Treatment for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinibINVICTUS
Sarcoma
GIST
-
INVICTUS
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Nivolumab
-
Taxane ChT docetaxel or paclitaxel
Recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine and platinum-based ChTATTRACTION-3
Gastrointestinal Cancers
Oesophageal Cancer
-
ATTRACTION-3
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Rucaparib
-
Single arm (Phase II)
BRCA mutation associated mCRPC previously treated with androgen receptor-directed therapy and a taxane-based ChTTRITON2
Genitourinary Cancers
Prostate cancer
BRCA mutation
TRITON2
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Pemigatinib
-
Single arm (Phase II)
Cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapyFIGHT-202
Gastrointestinal Cancers
Cholangiocarcinoma
FGFR2 gene fusion or rearrangement
FIGHT-202
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
Cobimetinib and vemurafenib
Placebo
Treatment for patients with BRAF V600 mutation-positive unresectable or metastatic melanomaIMspire150
Skin Cancers
Cutaneous Melanoma
BRAF V600
IMspire150
3
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
3
Capmatinib
-
Single arm
Treatment of adult patients with advanced non-small cell lung cancer harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapyGEOMETRY mono-1
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Capmatinib
-
Single arm
For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping GEOMETRY mono-1
Thoracic Malignancies
Non-small-cell Lung Cancer
METex14 skipping
GEOMETRY mono-1
3
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
3
Atezolizumab
-
Platinum-based chemotherapy
First-line treatment of patients with high PD-L1 expression ≥50% TC or ≥10% IC and who do not have EGFR mutant or ALK-positive NSCLCIMpower110
Thoracic Malignancies
Non-small-cell Lung Cancer
PD-L1 expression ≥50% TC or ≥10% IC
IMpower110
5
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
5
Pembrolizumab
ChT
Placebo plus ChT
Treatment of locally recurrent unresectable or metastaticTNBC in adults whose tumours express PD-L1 with a CPS ≥ 10 and who have not received prior chemotherapy KEYNOTE-355
Breast Cancer
Breast Cancer
Triple-negative, PD-L1 (CPS ≥10)
KEYNOTE-355
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Nivolumab
-
Single arm (Phase II)
Treatment after failure of prior platinum-containing therapy CheckMate 275
Genitourinary Cancers
Urothelial Carcinoma
-
CheckMate 275
1
PRELIMINARY SCORE
ORR
ADJUSTMENTS
FINAL SCORE
F3
1
Osimertinib
-
Placebo
Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutationsADAURA
Thoracic Malignancies
Non-small-cell Lung Cancer
EGFR exon 19 deletions or exon 21 (L858R) mutation
ADAURA
A
PRELIMINARY SCORE
DFS
ADJUSTMENTS
FINAL SCORE
F1
A
Margetuximab
ChT
Trastuzumab plus ChT
Treatment of adult patients who have received two or more prior anti-HER2 regimes, at least one of which was for metastatic diseaseSOPHIA
Breast Cancer
Breast Cancer
HER2+
SOPHIA
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Trastuzumab deruxtecan
-
ChT (irinitecan or paclitaxel)
Treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients who have received a prior trastuzumab-based regimenDESTINY-Gastric01
Gastrointestinal Cancers
Gastric or gastroesophageal junction adenocarcinoma
HER2+
DESTINY-Gastric01
4
PRELIMINARY SCORE
OS
ADJUSTMENTS
FINAL SCORE
F2a
4
Trabectedin
-
Dacarbazine
Treatment for patients with advanced soft-issue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients
Sarcoma
Soft tissue - Liposarcoma or leiomyosarcoma
-
-
2
PRELIMINARY SCORE
PFS
ADJUSTMENTS
FINAL SCORE
F2b
2
Watchlist
Tested Agent(s)
Combined Agent(s)
Control Arm
Treatment Setting
Tumour Type
Tumour Sub-type
Tumour Sub-group
Trial Name
Ref.
Score
Scorecard
Scorecard
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.